- Home
- PDCC vs ALEC Comparison
PDCC vs ALEC Comparison
Compare PDCC & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDCC
- ALEC
- Stock Information
- Founded
- PDCC N/A
- ALEC 2013
- Country
- PDCC
- ALEC United States
- Employees
- PDCC N/A
- ALEC N/A
- Industry
- PDCC
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PDCC
- ALEC Health Care
- Exchange
- PDCC NYSE
- ALEC Nasdaq
- Market Cap
- PDCC 123.0M
- ALEC 124.0M
- IPO Year
- PDCC N/A
- ALEC 2019
- Fundamental
- Price
- PDCC $17.85
- ALEC $1.63
- Analyst Decision
- PDCC
- ALEC Buy
- Analyst Count
- PDCC 0
- ALEC 7
- Target Price
- PDCC N/A
- ALEC $4.70
- AVG Volume (30 Days)
- PDCC N/A
- ALEC 541.7K
- Earning Date
- PDCC N/A
- ALEC 08-06-2025
- Dividend Yield
- PDCC N/A
- ALEC N/A
- EPS Growth
- PDCC N/A
- ALEC N/A
- EPS
- PDCC N/A
- ALEC N/A
- Revenue
- PDCC N/A
- ALEC $88,339,000.00
- Revenue This Year
- PDCC N/A
- ALEC N/A
- Revenue Next Year
- PDCC N/A
- ALEC $319.82
- P/E Ratio
- PDCC N/A
- ALEC N/A
- Revenue Growth
- PDCC N/A
- ALEC N/A
- 52 Week Low
- PDCC N/A
- ALEC $0.87
- 52 Week High
- PDCC N/A
- ALEC $6.78
- Technical
- Relative Strength Index (RSI)
- PDCC N/A
- ALEC 57.56
- Support Level
- PDCC N/A
- ALEC $1.41
- Resistance Level
- PDCC N/A
- ALEC $1.75
- Average True Range (ATR)
- PDCC 0.00
- ALEC 0.12
- MACD
- PDCC 0.00
- ALEC 0.01
- Stochastic Oscillator
- PDCC 0.00
- ALEC 67.90
About PDCC PEARL DIVER CREDIT COMPANY INC
PEARL DIVER CREDIT COMPANY INC is an externally managed, non-diversified, closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation by investing predominantly in third-party Collateralized Loan Obligation (CLO) equity and mezzanine tranches of predominately U.S.-dollar-denominated CLOs backed by corporate leveraged loans issued mainly to U.S. obligors.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.